Atrial fibrillation
KEYWORDS: fibrillation, atrial, atrial fibrillation, adults, quality, adults atrial, anticoagulation, data, statement, stroke, nice, source, local, risk, quality statement

healthcare professional's coagulometer which is checked in line with an external quality assurance scheme. Ensure accurate patient records are kept and shared appropriately. [NICE's HealthTech guidance on atrial fibrillation and heart valve disease: self-monitoring coagulation status using point- of-care coagulometers (the CoaguChek XS system), recommendations 1.3 and 1.4] Equality and diversity considerations For adults with atrial fibrillation who may have difficulty with or who are unable to self-monitor, such as people with disabilities, the possibility of their carers helping with self-monitoring should be considered. Coagulometers currently come at a cost to the adult with atrial fibrillation, so reasonable adjustments should be made for the socioeconomic status of the adult. Update information February 2018: The source guidance and definitions for statement 6 have been updated to ensure alignment with the updated NICE diagnostics guidance on self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system). In statement 3, the rationale and definition sections have been changed to include edoxaban as an option for anticoagulation to reflect NICE technology appraisal guidance on edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation. Minor changes since publication December 2025: Links have been updated throughout to NICE's HealthTech guidance 353, which
